Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Aug 8;280(2):201-10.
doi: 10.1016/j.canlet.2009.01.002. Epub 2009 Jan 31.

Development of Vorinostat: Current Applications and Future Perspectives for Cancer Therapy

Affiliations
Review

Development of Vorinostat: Current Applications and Future Perspectives for Cancer Therapy

Victoria M Richon et al. Cancer Lett. .

Abstract

Vorinostat is a potent histone deacetylase inhibitor that blocks the catalytic site of these enzymes. A large number of cellular proteins are modified post-translationally by acetylation, leading to altered structure and/or function. Many of these proteins, such as core nucleosomal histones and transcription factors, function in key cellular processes and signal transduction pathways that regulate cell growth, migration, and differentiation. At concentrations that are non-toxic to normal cells, vorinostat dramatically alters cellular acetylation patterns and causes growth arrest and death and in a wide range of transformed cells, both in vitro and in animal tumor models. Vorinostat has shown promising clinical activity against hematologic and solid tumors at doses that have been well tolerated by patients. Recent non-clinical experiments that explored the effects of vorinostat in combination with other chemotherapeutic agents have begun to illuminate potential mechanisms of action for this histone deacetylase inhibitor and are providing guidance for new avenues of clinical investigation.

Similar articles

See all similar articles

Cited by 60 articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback